Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis

• Published in: PloS one 2023-01, Vol.18 (1), p.e0278685-e0278685
• Main Authors: Yeh, Tzu-Lin, Tsai, Ming-Chieh, Tsai, Wen-Hsuan, Tu, Yu-Kang, Chien, Kuo-Liong
• Format: Article
• Language: English
• Subjects: Adult; Adults; Age; Agonists; Analysis; Asymmetry; Bias; Biology and life sciences; Body mass index; Body Weight; Care and treatment; Complications and side effects; Correlation; Correlation coefficient; Correlation coefficients; Diabetes; Diabetes Mellitus, Type 2; Diabetes therapy; Diabetics; Diet therapy; Dosage and administration; FDA approval; GLP-1 receptor agonists; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor - agonists; Glucose monitors; Glycated Hemoglobin; Glycemic Control; Glycosylated hemoglobin; Health aspects; Hemoglobin; Heterogeneity; Humans; Hypoglycemic Agents; Insulin resistance; Medical ethics; Medicine and health sciences; Meta-analysis; Metabolism; Modelling; Multivariate analysis; Multivariate statistical analysis; Obesity; Overweight; Patient outcomes; Peptides; Physical Sciences; Physiological aspects; Randomized Controlled Trials as Topic; Receptors; Research and Analysis Methods; Science Policy; Statistical analysis; Structural equation modeling; Subgroups; Weight Loss; Weight reduction
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0278685

To explore the effect of glucagon-like peptide-1 receptor agonist (GLP-1 RAs) on glycemic control and weight reduction in adults. Databases were searched from August 2021 to March 2022. Data were analyzed using mean difference (MD) values with 95% confidence intervals (CIs). Both random-and fixed-effect models were employed. Heterogeneity was explored using pre-specified subgroup analyses and meta-regression. Structural equation modeling fitting was used for the multivariate meta-analysis. A total of 31 double-blind randomized controlled trials with 22,948 participants were included in the meta-analysis. The MD and 95% CI of the pooled GLP1-RA-induced change in the glycated hemoglobin level was -0.78% (-0.97%, -0.60%) in the random-effects model and -0.45% (-0.47%, -0.44%) in the fixed-effect model, with a high heterogeneity (I2 = 97%). The pooled body weight reduction was -4.05 kg (-5.02 kg, -3.09 kg) in the random-effects model and -2.04 kg (-2.16 kg, -1.92 kg) in the fixed-effect model (I2 = 98%). The standardized pooled correlation coefficient between HbA1c levels and body weight was -0.42. A negative correlation between glycemic control and weight reduction was obtained. Long-acting GLP-1 RAs significantly reduced the glycated hemoglobin level and body weight in adults.